Adaptimmune Therapeutics plc (ADAP)
| Market Cap | 176.98M |
| Revenue (ttm) | 70.77M |
| Net Income (ttm) | -91.02M |
| Shares Out | 226.17M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252,006 |
| Open | 0.770 |
| Previous Close | 0.768 |
| Day's Range | 0.750 - 0.785 |
| 52-Week Range | 0.680 - 2.650 |
| Beta | 2.22 |
| Analysts | Buy |
| Price Target | 4.92 (+528.75%) |
| Earnings Date | Nov 7, 2023 |
About ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreemen... [Read more]
Financial Performance
In 2022, ADAP's revenue was $27.15 million, an increase of 341.50% compared to the previous year's $6.15 million. Losses were -$165.46 million, 4.66% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is $4.92, which is an increase of 528.75% from the latest price.
News
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces th...
Adaptimmune Reports Second Quarter Financial Results and Business Update
Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023 Tran...
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial ...
Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesoth...
Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO
Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022) Median...
Adaptimmune Reports First Quarter Financial Results and Business Update
Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumor Adaptimmune and GSK agreed terms f...
Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report finan...
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutic...
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials for ...
ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. is fair to Adapt...
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed engineered TCR T-cell therapy for a solid tumor 52% (13/25) response rate...
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial m...
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fi...
Adaptimmune Announces Changes to Board of Directors
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in T-cell therapy to treat cancer, today announced t...
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel -- Based on these results, the Company initiated a Phase 2 trial with afami-cel for...
Adaptimmune Reports Third-Quarter Financial Results and Business Update
Adaptimmune will focus on programs in MAGE-A4 and PRAME, two of the most validated T-Cell targets in solid tumors Adaptimmune will initiate a rolling BLA submission for afami-cel for the treatment of ...
Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
New responses in ovarian and urothelial cancers increase ORR to 52% from 44% in heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers after single dose of ADP-A2M4C...
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fin...
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
Adaptimmune gains full control of late-stage preclinical optimized PRAME TCR; IND-ready in 2023 –GSK to deliver data from the ongoing Phase 2 / potential registrational trial with lete-cel in sarcoma ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adaptimmune Therapeutics plc - ADAP
New York, New York--(Newsfile Corp. - September 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Adaptimmune Therapeutics plc ("Adaptimmune" or the "Company") (NASDAQ: ADAP)...
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development pl...
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials
- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a l...
Adaptimmune Reports Second-Quarter Financial Results and Business Update
- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phas...
Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financ...
Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) -- Responses occurred across subgroups, with greater response ...